IP Library › Granted Patent US 12,514,924
Granted Patent B2
US 12,514,924 · App. 17/818,188 · Granted Jan 6, 2026

Humanized anti-CD40 antibodies and uses thereof

Inventors: Bo Yu (Lexington, MA); Rijian Wang (Lexington, MA); Keith Reimann (Lexington, MA)
Assignee: Primatope Therapeutics Inc.
A61K39/39558A61K31/436A61K39/395A61K39/3955A61K45/06C07K16/18C07K16/2866C07K16/2878A61K38/00A61K2039/505C07K2317/24C07K2317/33C07K2317/76C07K2317/92C07K2317/94Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,514,924
App. No.
17/818,188
Granted
Jan 6, 2026
Kind
B2
Abstract

The present disclosure relates to anti-CD40 antibodies, such as humanized anti-CD40 antibodies, that may be used in various therapeutic, prophylactic and diagnostic methods. The antibodies generally block the ability of CD40 to bind CD154 and do so without activating the cell expressing CD40 (e.g., a B cell). The present antibodies or fragments thereof may be used to reduce complications associated with organ or tissue transplantation.

Claims (15)

1 . A method of producing a humanized anti-CD40 antibody or antigen-binding fragment thereof, the method comprising:

(a) culturing a eukaryotic cell comprising a polynucleotide encoding the humanized anti-CD40 antibody or antigen-binding fragment thereof or a vector comprising the polynucleotide, wherein the antibody or antigen-binding fragment comprises a heavy chain variable region comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence set forth in any one of SEQ ID NOs: 19, 20, 21, 24, 25, and 26 and a light chain variable region comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence set forth in any one of SEQ ID NOs: 22, 23, 27, 28 and 29, wherein the heavy chain variable region comprises a CDR1, CDR2, and CDR3 with the amino acid sequences set forth in SEQ ID NOs: 13, 14, and 15, respectively, and wherein the light chain variable region comprises a CDR1, CDR2, and CDR3 with the amino acid sequences set forth in SEQ ID NOs: 16, 17, and 18, respectively; wherein the culturing occurs in culture medium under conditions wherein the antibody or antigen-binding fragment thereof is expressed, thereby producing the humanized anti-CD40 antibody or antigen-binding fragment thereof; and

(b) recovering the anti-CD40 antibody or antigen-binding fragment thereof from the cell or culture medium.

2 . The method of claim 1 , wherein the amino acid sequence of the heavy chain variable region has at least 90% sequence identity to the amino acid sequence set forth in any one of SEQ ID NOs: 19, 20, 21, 24, 25, and 26, and the amino acid sequence of the light chain variable region has at least 90% sequence identity to the amino acid sequence set forth in any one of SEQ ID NOs: 22, 23, 27, 28 and 29.

3 . The method of claim 2 , wherein the amino acid sequence of the heavy chain variable region comprising an amino acid sequence has at least 95% identity to the amino acid sequences set forth in any one of SEQ ID NOs: 19, 20, 21, 24, 25, and 26, and the amino acid sequence of the light chain variable region has at least 95% sequence identity to the amino acid sequences set forth in any one of SEQ ID NOS:

22, 23, 27, 28 and 29.

4 . The method of claim 3 , wherein the amino acid sequence of the heavy chain variable region comprises the amino acid sequence set forth in any one of SEQ ID NOs: 19, 20, 21, 24, 25, and 26, and the amino acid sequence of the light chain variable region comprises the amino acid sequence set forth in any one of SEQ ID NOs: 22, 23, 27, 28 and 29, wherein the antibody or antigen-binding fragment thereof does not comprise the heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 21 and the light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 23.

5 . The method of claim 1 , wherein the humanized anti-CD40 antibody or antigen-binding fragment thereof comprises at least one human constant domain.

6 . The method of claim 1 , wherein the eukaryotic cell is a yeast cell, plant cell, insect cell, or mammalian cell.

7 . The method of claim 6 , wherein the eukaryotic cell is a mammalian cell.

8 . The method of claim 7 , wherein the mammalian cell is a monkey kidney cell, HEK293 cell, baby hamster kidney cell, Chinese hamster ovary (CHO) cell, NS0 cell, PerC6 cell, BSC-1 cell, human hepatocellular carcinoma cell, SP2/0, HeLa, Madin-Darby bovine kidney cell, myeloma cell, or lymphoma cell.

9 . The method of claim 8 , wherein the mammalian cell is a CHO cell.

10 . The method of claim 8 , wherein the monkey kidney cell is a COS-1 or COS-7 cell.

11 . The method of claim 8 , wherein the baby hamster kidney cell is a BHK21 cell.

12 . The method of claim 8 , wherein the human hepatocellular carcinoma cell is a HEP G2 cell.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 12, 2022
From: YU, BO; WANG, RIJIAN; REIMANN, KEITH
To: PRIMATOPE THERAPEUTICS INC.
Reel/Frame 060793/0613 →
Continuity (7)
Division 16994249 · Aug 14, 2020
Division 16234110 · Dec 27, 2018
Continuation 15955393 · Apr 17, 2018
Division 15829352 · Dec 1, 2017
Continuation PCTUS2016050114 · Sep 2, 2016
Provisional Application 62214411 · Sep 4, 2015
Related Publication 20220387587A1 · Dec 8, 2022
References Cited (221)
US 5225539A · Winter · 1993 [cited by applicant]
US 5677165A · de Boer et al. · 1997 [cited by applicant]
US 5693761A · Queen et al. · 1997 [cited by applicant]
US 5693762A · Queen et al. · 1997 [cited by applicant]
US 5801227A · Fanslow, III et al. · 1998 [cited by applicant]
US 5874082A · de Boer · 1999 [cited by applicant]
US 6004552A · de Boer et al. · 1999 [cited by applicant]
US 6051228A · Aruffo et al. · 2000 [cited by applicant]
US 6054297A · Carter et al. · 2000 [cited by applicant]
US 6056959A · de Boer et al. · 2000 [cited by applicant]
US 6132978A · Gelfand et al. · 2000 [cited by applicant]
US 6280957B1 · Sayegh et al. · 2001 [cited by applicant]
US 6312693B1 · Aruffo et al. · 2001 [cited by applicant]
US 6315998B1 · de Boer et al. · 2001 [cited by applicant]
US 6413514B1 · Aruffo et al. · 2002 [cited by applicant]
US 6632927B2 · Adair et al. · 2003 [cited by applicant]
US 7063845B2 · Mikayama et al. · 2006 [cited by applicant]
US 7193064B2 · Mikayama et al. · 2007 [cited by applicant]
US 7288251B2 · Bedian et al. · 2007 [cited by applicant]
US 7361345B2 · de Boer et al. · 2008 [cited by applicant]
US 7445780B2 · Chu et al. · 2008 [cited by applicant]
US 7498032B2 · Siegall et al. · 2009 [cited by applicant]
US 7537763B2 · Mikayama et al. · 2009 [cited by applicant]
US 7790166B2 · de Boer et al. · 2010 [cited by applicant]
US 8106164B2 · Gellerfors et al. · 2012 [cited by applicant]
US 8138134B2 · Zhang et al. · 2012 [cited by applicant]
US 8226952B2 · Thomas, Jr. et al. · 2012 [cited by applicant]
US 8277810B2 · Long et al. · 2012 [cited by applicant]
US 8303955B2 · Presta et al. · 2012 [cited by applicant]
US 8435514B2 · Perrin et al. · 2013 [cited by applicant]
US 8591900B2 · Barrett et al. · 2013 [cited by applicant]
US 8784823B2 · Burkly et al. · 2014 [cited by applicant]
US 8828396B2 · Heusser et al. · 2014 [cited by applicant]
US 8911726B2 · Takahashi et al. · 2014 [cited by applicant]
US 9023360B2 · Takahashi et al. · 2015 [cited by applicant]
US 9023361B2 · Takahashi et al. · 2015 [cited by applicant]
US 9125893B2 · Endo et al. · 2015 [cited by applicant]
US 9475879B2 · Suri et al. · 2016 [cited by applicant]
US 9598494B2 · Takahashi et al. · 2017 [cited by applicant]
US 9974855B2 · Yu et al. · 2018 [cited by applicant]
US 9987356B2 · Reimann et al. · 2018 [cited by applicant]
US 10201608B2 · Yu et al. · 2019 [cited by applicant]
US 10561728B2 · Reimann et al. · 2020 [cited by applicant]
US 10772958B2 · Yu et al. · 2020 [cited by applicant]
US 11439706B2 · Yu et al. · 2022 [cited by applicant]
US 12234294B2 · Kranz · 2025 [cited by applicant]
US 20020031512A1 · Pasch et al. · 2002 [cited by applicant]
US 20030211100A1 · Bedian et al. · 2003 [cited by applicant]
US 20040110226A1 · Lazar et al. · 2004 [cited by applicant]
US 20040120948A1 · Mikayama et al. · 2004 [cited by applicant]
US 20050118166A1 · Yellin et al. · 2005 [cited by applicant]
US 20070110754A1 · Long et al. · 2007 [cited by applicant]
US 20070190051A1 · Bedian et al. · 2007 [cited by applicant]
US 20070218060A1 · Long et al. · 2007 [cited by applicant]
US 20080085531A1 · Den Hartog et al. · 2008 [cited by applicant]
US 20090123466A1 · Mikayama et al. · 2009 [cited by applicant]
US 20090202531A1 · Aukerman et al. · 2009 [cited by applicant]
US 20090304706A1 · Lu et al. · 2009 [cited by applicant]
US 20090311268A1 · Thomas et al. · 2009 [cited by applicant]
US 20100098694A1 · Bedian et al. · 2010 [cited by applicant]
US 20100234578A1 · Mikayama et al. · 2010 [cited by applicant]
US 20100239575A1 · Banchereau et al. · 2010 [cited by applicant]
US 20110027276A1 · Bernett et al. · 2011 [cited by applicant]
US 20110243932A1 · Barrett et al. · 2011 [cited by applicant]
US 20120121585A1 · Heusser et al. · 2012 [cited by applicant]
US 20130323267A1 · Endo et al. · 2013 [cited by applicant]
US 20140093497A1 · Reimann et al. · 2014 [cited by applicant]
US 20150110783A1 · Lu et al. · 2015 [cited by applicant]
US 20180078640A1 · Yu et al. · 2018 [cited by applicant]
US 20180280507A1 · Yu et al. · 2018 [cited by applicant]
US 20180344845A1 · Reimann et al. · 2018 [cited by applicant]
US 20190117771A1 · Yu et al. · 2019 [cited by applicant]
US 20200261547A1 · Kost et al. · 2020 [cited by applicant]
US 20200384107A1 · Yu et al. · 2020 [cited by applicant]
US 20210079093A1 · Willingham et al. · 2021 [cited by applicant]
US 20220133887A1 · Reimann et al. · 2022 [cited by applicant]
US 20220387587A1 · Yu et al. · 2022 [cited by applicant]
US 20230183367A1 · Paolini et al. · 2023 [cited by applicant]
US 20230203179A1 · Kranz · 2023 [cited by applicant]
US 20230279135A1 · Kranz · 2023 [cited by applicant]
US 20230287132A1 · Paolini et al. · 2023 [cited by applicant]
CN 103596593A · 2014 [cited by applicant]
EP 1297017 · 2003 [cited by applicant]
EP 1682180 · 2006 [cited by applicant]
EP 1707627A1 · 2006 [cited by applicant]
EP 1945260 · 2008 [cited by applicant]
EP 1682180B1 · 2009 [cited by applicant]
EP 1297017B1 · 2012 [cited by applicant]
EP 1945260B1 · 2012 [cited by applicant]
JP 2005508176A · 2005 [cited by applicant]
JP 2007513073A · 2007 [cited by applicant]
JP 2009513712A · 2009 [cited by applicant]
JP 2011503098A · 2011 [cited by applicant]
WO WO0198357A2 · 2001 [cited by applicant]
WO WO03040170A2 · 2003 [cited by applicant]
WO WO2005044307A2 · 2005 [cited by applicant]
WO WO2005044854A2 · 2005 [cited by applicant]
WO WO2007053661A2 · 2007 [cited by applicant]
WO WO2007053767A1 · 2007 [cited by applicant]
WO WO2007075326A2 · 2007 [cited by applicant]
WO WO2008118356A2 · 2008 [cited by applicant]
WO WO2009062054A1 · 2009 [cited by applicant]
WO WO2010065819A1 · 2010 [cited by applicant]
WO WO2012065950A1 · 2012 [cited by applicant]
WO WO2012111762A1 · 2012 [cited by applicant]
WO WO2012125569A2 · 2012 [cited by applicant]
WO WO2013164789A2 · 2013 [cited by applicant]
WO WO2014121099A1 · 2014 [cited by applicant]
WO WO2016119909A1 · 2016 [cited by applicant]
WO WO2016126702A1 · 2016 [cited by applicant]
WO WO2017004006A1 · 2017 [cited by applicant]
WO WO2017040932A1 · 2017 [cited by applicant]
WO WO2020078453A1 · 2020 [cited by applicant]
WO WO2022061061A1 · 2022 [cited by applicant]
WO WO2023044048A1 · 2023 [cited by applicant]
WO WO2023081641A1 · 2023 [cited by applicant]
WO WO2023081831A2 · 2023 [cited by applicant]
WO WO2025045766A1 · 2025 [cited by applicant]
WO WO2025169146A1 · 2025 [cited by applicant]
International Search Report and Written Opinion for PCT/US2022/079072, mailed Feb. 8, 2023 (23 pages). [cited by applicant]
International Search Report and Written Opinion for PCT/US2023/060358, dated May 30, 2023 (16 pages). [cited by applicant]
Kheddo et al., “The effect of arginine glutamate on the stability of monoclonal antibodies in solution,” Int J Pharm. 473(1-2):126-133 (Oct. 2014). [cited by applicant]
Strickley et al., “A review of Formulations of Commercially Available Antibodies,” J Pharm Sci. 110(7):2590-2608 (Jul. 2021) (75 pages). [cited by applicant]
Adams et al., “Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival,” J Immunol. 174(1):542-50 (2005). [cited by applicant]
Albach et al., “Safety, pharmacokinetics, and pharmacodynamics of single rising doses of BI 655064, an antagonistic anti-CD40 antibody in healthy subjects: a potential novel treatment for autoimmune disease,” Eur J Clin… [cited by applicant]
Almagro et al., “Humanization of antibodies,” Front Biosci. 13:1619-33 (2008). [cited by applicant]
Aoyagi et al., “A human anti-CD40 monoclonal antibody, 4D11, for kidney transplantation in cynomolgus monkeys: induction and maintenance therapy,” Am J Transplant. 9(8):1732-41 (2009). [cited by applicant]
Apexigen Inc., APX005M Briefing Materials, Oncologic Drugs Advisory Committee, Jun. 21, 2017 (22 pages). [cited by applicant]
Badell et al., “Nondepleting anti-CD40-based therapy prolongs allograft survival in nonhuman primates,” Am J Transplant. 12(1):126-35 (2012). [cited by applicant]
Bankert et al., “Induction of an altered CD40 signaling complex by an antagonistic human monoclonal antibody to CD40,” J Immunol. 194(9):4319-27 (2015). [cited by applicant]
Boon et al., “Preclinical assessment of anti-CD40 Mab 5D12 in cynomolgus monkeys,” Toxicology. 174(1):53-65 (2002). [cited by applicant]
Boon et al., “Prevention of experimental autoimmune encephalomyelitis in the common marmoset ( [cited by applicant]
Carpenter et al., “Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation,” J Transl Med. 7:93 (2009) (10 pages). [cited by applicant]
Carter et al., “Humanization of an anti-p185HER2 antibody for human cancer therapy,” Proc Natl Acad Sci U.S.A. 89(10):4285-9 (1992). [cited by applicant]
Chamberlain et al., “Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease a… [cited by applicant]
Chen et al., “Enhancement and destruction of antibody function by somatic mutation: unequal occurrence is controlled by V gene combinatorial associations,” EMBO J. 14(12):2784-94 (1995). [cited by applicant]
Colman, “Effects of amino acid sequence changes on antibody-antigen interactions,” Res Immunol. 145(1):33-6 (1994). [cited by applicant]
Communication and substantive Office Action for European Patent Application No. 12758099.1, dated Dec. 22, 2016 (7 pages). [cited by applicant]
Communication for European Application No. 12758099.1-1412, mailed Aug. 26, 2014 (7 pages). [cited by applicant]
Cooper et al., “Platelet-associated antibodies, cellular immunity and FCGR3a genotype influence the response to rituximab in immune thrombocytopenia,” Br J Haematol. 158(4):539-47 (2012). [cited by applicant]
Cordoba et al., “A novel, blocking, Fc-silent anti-CD40 monoclonal antibody prolongs nonhuman primate renal allograft survival in the absence of B cell depletion,” Am J Transplant. 15(11):2825-36 (2015). [cited by applicant]
Daniluk et al., “SAT0147 Safety and Efficacy of BI 655064, An Antagonistic Anti-CD40 Antibody in Rheumatoid Arthritis (RA) Patients,” Ann Rheum Dis. 75(suppl 2) (2016) (3 pages) (Abstract only). [cited by applicant]
De Boer et al., “Generation of monoclonal antibodies to human lymphocyte cell surface antigens using insect cells expressing recombinant proteins,” J Immunol Methods. 152(1):15-23 (1992). [cited by applicant]
Denton et al., “Central role for CD40/CD40 ligand (CD154) interactions in transplant rejection,” Pediatr Transplant. 2(1):6-15 (1998). Abstract Only. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/10084754> on Nov. … [cited by applicant]
Wu, Chapter 12: Simultaneous Humanization and Affinity Optimization of Monoclonal Antibodies. [cited by applicant]
Extended European Search Report for European Patent Application No. 16843066.8, dated Apr. 26, 2018 (11 pages). [cited by applicant]
Final Rejection for Japanese Application No. 2013-557941, dated Mar. 7, 2017 (10 pages). [cited by applicant]
First Examination Report for Australian Patent Application No. 2012229236, issued May 4, 2016 (4 pages). [cited by applicant]
First Examination Report for Australian Patent Application No. 2017216556, issued Nov. 30, 2018 (6 pages). [cited by applicant]
Fourth Office Action for Chinese Application No. 201280022277.3, issued Dec. 2, 2015 (8 pages). [cited by applicant]
Gershoni et al., “Epitope mapping—the first step in developing epitope-based vaccines,” BioDrugs. 21(3):145-56 (2007). [cited by applicant]
Gilson et al., “Anti-CD40 monoclonal antibody synergizes with CTLA4-Ig in promoting long-term graft survival in murine models of transplantation,” J Immunol. 183(3):1625-35 (2009). [cited by applicant]
Grammer et al., “Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions,” J Clin Invest. 112(10):1506-20 (2003). [cited by applicant]
Haanstra et al., “Prevention of kidney allograft rejection using anti-CD40 and anti-CD86 in primates.” Transplantation. 75(5):637-43 (2003). [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2012/028782, mailed Sep. 14, 2012 (11 pages). [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2016/050114, mailed Jan. 19, 2017 (15 pages). [cited by applicant]
Kettleborough et al., “Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation,” Protein Eng. 4(7):773-83 (1991). [cited by applicant]
Kim et al., “Costimulation blockade alters germinal center responses and prevents antibody-mediated rejection,” available in PMC Apr. 14, 2014, published in final edited form as :Am J Transplant. 14(1):59-69 (2014) (19 … [cited by applicant]
Kim et al., “Fc-Silent Anti-CD154 Domain Antibody Effectively Prevents Nonhuman Primate Renal Allograft Rejection,” available in PMC May 1, 2018, published in final edited form as: Am J Transplant. 17(5):1182-92 (2017) … [cited by applicant]
Kussie et al., “A Single Engineered Amino Acid Substitution Changes Antibody Fine Specificity,” J Immunol. 152(1):146-52 (1994). [cited by applicant]
Kuwana et al., “Effect of a single injection of humanized anti-CD154 monoclonal antibody on the platelet-specific autoimmune response in patients with immune thrombocytopenia purpura,” Blood. 103(4):1229-36 (2004). [cited by applicant]
Lazar et al., “A Molecular Immunology Approach To Antibody Humanization and Functional Optimization,” Molecular Immunol. 44(8): 1986-98 (2007) (Abstract only). [cited by applicant]
Lee et al., “In vitro testing of an anti-CD40 monoclonal antibody, clone 2010, in primates and pigs,” available in PMC Nov. 1, 2016, published in final edited form as: Transpl Immunol. 33(3):185-191 (2015) (17 pages). [cited by applicant]
Liu et al., “Agonistic antibody to CD40 boosts the antitumor activity of adoptively transferred T cells in vivo,” 35(3):276-82 (2012). [cited by applicant]
Lowe et al., “A novel monoclonal antibody to CD40 prolongs islet allograft survival,” Am J Transplant. 12(8):2079-87 (2012). [cited by applicant]
Luqman et al., “The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells,” Blood. 112(3):711-20 (2008). [cited by applicant]
Mohiuddin MM, Singh AK, Corcoran PC, et al. Chimeric 2010R4 anti-CD40 antibody therapy is critical for long-term survival of GTKO.hCD46.hTBM pig-to-primate cardiac xenograft. [cited by applicant]
Mohiuddin et al., “Role of anti-CD40 antibody-mediated costimulation blockade on non-Gal antibody production and heterotopic cardiac xenograft survival in a GTKO.hCD46Tg pig-to-baboon model,” available in PMC Sep. 18, 2… [cited by applicant]
Molano et al., “Prolonged islet allograft survival in diabetic NOD mice by targeting CD45RB and CD154,” Diabetes. 52(4):957-64 (2003). [cited by applicant]
Morris, Epitope mapping of protein antigens by competition ELISA. The Protein Protocols Handbook. Humana Press, 595-600 (1996). [cited by applicant]
Najafian et al., “CTLA4-Ig: a novel immunosuppressive agent,” Expert Opin Investig Drugs. 9(9):2147-57 (2000). [cited by applicant]
O'Neill et al,. “Comparative Evaluation of alphaCD40 (2010R4) and alphaCD154 (5C8H1 and IDEC-131) in a Nonhuman Primate Cardiac Allotransplant Model,” available in PMC Sep. 1, 2018, published in final edited form as: Tr… [cited by applicant]
Office Action for Chinese Application No. 201280022277.3, mailed Aug. 25, 2014 (19 pages). [cited by applicant]
Office Action for Japanese Application No. 2013-557941, dated Jul. 26, 2016 (8 pages). [cited by applicant]
Office Action for Japanese Application No. 2013-557941, mailed Oct. 27, 2015 (16 pages). [cited by applicant]
Okimura et al. “Characterization of ASKP1240, a fully human antibody targeting human CD40 with potent immunosuppressive effects,” Am J Transplant. 14(6):1290-99 (2014). [cited by applicant]
Oura et al., “Long-term hepatic allograft acceptance based on CD40 blockade by ASKP1240 in nonhuman primates,” Am J Transplant. 12(7):1740-54 (2012). [cited by applicant]
Pearson et al., “Anti-CD40 therapy extends renal allograft survival in rhesus macaques,” Transplantation. 74(7):933-40 (2002). [cited by applicant]
Queen et al., “A humanized antibody that binds to the interleukin 2 receptor,” Proc Natl Acad Sci U S A. 86(24):10029-33 (1989). [cited by applicant]
Reimann, “Epitope Correction,” (2 pages). [cited by applicant]
Roguska et al., “Humanization of murine monoclonal antibodies through variable domain resurfacing,” Proc Natl Acad Sci U.S.A. 91(3):969-73 (1994). [cited by applicant]
Rudikoff et al., “Single amino acid substitution altering antigen-binding specificity,” Proc Natl Acad Sci U S A. 79(6):1979-83 (1982). [cited by applicant]
Russo et al., “Platelet-activating factor mediates CD40-dependent angiogenesis and endothelial-smooth muscle cell interaction,” J Immunol. 171(10):5489-97 (2003). [cited by applicant]
Schwabe et al., “FRI0168 Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BI 655064, An Antagonistic Anti-CD40 Antibody in Healthy Volunteers,” Ann Rheum Dis. 74(suppl 2) (2015) (3 pages) (Abstra… [cited by applicant]
Second Office Action for Chinese Application No. 201280022277.3, issued Mar. 24, 2015 (12 pages). [cited by applicant]
Sho et al., “Requirements for induction and maintenance of peripheral tolerance in stringent allograft models,” Proc Natl Acad Sci USA. 102(37):13230-5 (2005). [cited by applicant]
Shock et al., “CDP7657, an anti-CD40L antibody lacking an Fc domain, inhibits CD40L-dependent immune responses without thrombotic complications: an in vivo study,” Arthritis Res Ther. 17:234 (2015) (12 pages). [cited by applicant]
Slade et al., “Assessment of Safety, Pharmacokinetics and Pharmacodynamics of a Novel Anti-CD40 Monoclonal Antibody, CFZ533, in Healthy Volunteers and in Rheumatoid Arthritis Patients,” 2016 ACR/ARHP Annual Meeting, Nov… [cited by applicant]
Strohl, “Optimization of Fc-mediated effector functions of monoclonal antibodies,” Curr Opin Biotechnol. 20(6):685-91 (2009). [cited by applicant]
Sutherland et al., “Anti-CD45RB antibody deters xenograft rejection by modulating T cell priming and homing,” Int Immunol. 14(8):953-62 (2002). [cited by applicant]
Third Office Action for Chinese Application No. 201280022277.3, issued Aug. 24, 2015 (10 pages). [cited by applicant]
Thompson et al., “CD40-specific costimulation blockade enhances neonatal porcine islet survival in nonhuman primates,” Am J Transplant. 11(5):947-57 (2011). [cited by applicant]
Visvanathan et al., “FRI0231 Treatment with BI 655064 (Antagonistic Anti-CD40 Antibody) Modulates Biomarkers Associated with Rheumatoid Arthritis (RA),” Ann Rhem Dis. 75(suppl 2) (2016) (3 pages) (Abstract only). [cited by applicant]
Visvanathan et al., “Treatment with BI 655064 (Antagonistic Anti-CD40 Antibody) Modulates Clinical and Biomarker Parameters Associated with Rheumatoid Arthritis (RA),” Scientific Abstracts, p. 517 Jun. 10, 2016. [cited by applicant]
Winter et al., “Humanized antibodies,” Trends Pharmacol Sci. 14(5):139-43 (1993). [cited by applicant]
Yamniuk et al., “Functional Antagonism of Human CD40 Achieved by Targeting a Unique Species-Specific Epitope,” J Mol Biol. 428(14):2860-79 (2016). [cited by applicant]
Malmborg Hager et al., “Affinity and epitope profiling of mouse anti-CD40 monoclonal antibodies,” Scand J Immunol. 57(6):517-24 (2003). [cited by applicant]
Kasran et al., “Safety and tolerability of antagonist anti-human CD40 Mab ch5D12 in patients with moderate to severe Crohn's disease,” Aliment Pharmacol Ther. 22(2):111-22 (2005). [cited by applicant]
Extended European Search Report for European Application No. 19156093.7, mailed Sep. 25, 2019 (8 pages). [cited by applicant]
D'Angelo et al., “Many Routes to an Antibody Heavy-Chain CDR3: Necessary, Yet Insufficient, for Specific Binding,” Front Immunol. 9:395 (2018) (13 pages). [cited by applicant]
Piche-Nicholas et al., “Changes in Complementarity-Determining Regions Significantly Alter IgG Binding to the Neonatal Fc Receptor (FcRn) and Pharmacokinetics,” MAbs. 10(1):81-94 (2018). [cited by applicant]
Vonderheide et al., “Agonistic CD40 Antibodies and Cancer Therapy,” Clin Cancer Res. 19(5):1035-1043 (2013) (10 pages). [cited by applicant]
Extended European Search Report for European Patent Application No. 21156562.7 dated Oct. 8, 2021 (13 pages). [cited by applicant]
First Examination Report for Australian Patent Application No. 2016315873, dated Mar. 30, 2022 (3 pages). [cited by applicant]
Office Action for Canadian Patent Application No. 3,122,934, dated Jul. 25, 2022 (3 pages). [cited by applicant]
Wang et al., “Antibody structure, instability, and formulation,” J Pharm Sci. 96(1):1-26 (Jan. 2007). [cited by applicant]
[cited by applicant]
Genovese et al., “Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate,” Arthritis Rheumatol. 68(12):2857-286… [cited by applicant]
Visvanathan et al., “Effects of BI 655064, an antagonistic anti-CD40 antibody, on clinical and biomarker variables in patients with active rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase IIa … [cited by applicant]
Extended European Search Report for European Patent Application No. 23212999.9, dated Apr. 16, 2024 (9 pages). [cited by applicant]
Margolis et al., “Long-acting antiviral agents for HIV treatment,” Curr Opin HIV AIDS. 10(4):246-52 (Jul. 2015). [cited by applicant]
Kang et al., “Rapid Formulation Development for Monoclonal Antibodies,” BioProcess International. 14(4):40-45 (Apr. 2016) (4 pages). [cited by applicant]
Bramham et al., “Stability of a high-concentration monoclonal antibody solution produced by liquid-liquid phase separation,” MAbs. 13(1):1940666 (Jul. 2021) (8 pages). [cited by applicant]
Moel et al., “In rheumatoid arthritis, changes in autoantibody levels reflect intensity of immunosuppression, not subsequent treatment response”, Arthritis Research & Therapy. 21:28 (Jan. 2019) (8 pages). [cited by applicant]
Wilson, “Rheumatoid factors in patients with rheumatoid arthritis”, Canadian Family Physician. 52 (Feb. 2006) (2 pages). [cited by applicant]
Bruns et al, “Prospective cohort study of effects of infliximab on rheumatoid factor, anti-cyclic citrullinated peptide antibodies and antinuclear antibodies in patients with long-standing rheumatoid arthritis”, Joint B… [cited by applicant]
Muralidharan et al., “Preclinical Immunopharmacologic Assessment of KPL-404, a Novel, Humanized, Non-Depleting Antagonistic Anti-CD40 Monoclonal Antibody,” J Pharmacol Exp Ther. 381(1):12-21 (Jan. 2022). [cited by applicant]
Papandrikopoulou et al., “Dose-Dependent Suppression of T Cell-Dependent Antibody Response in Healthy Volunteers by KPL-404, an Anti-CD40 Monoclonal Antibody, Supports Chronic Dosing Study in Patients With Rheumatoid Ar… [cited by applicant]
Zhong et al., “Repeated Systemic Dosing of Adeno-Associated Virus Vectors in Immunocompetent Mice After Blockade of T Cell Costimulatory Pathways,” Human Gene Ther. 33(5-6):290-300 (Mar. 2022). [cited by applicant]
Ziegler et al., “Correction of Enzymatic and Lysosomal Storage Defects in Fabry Mice by Adenovirus-Mediated Gene Transfer,” Human Gene Ther. 10:1667-1682 (Jul. 1999). [cited by applicant]
Samant et al., “First-in-Human Phase 1 Randomized Trial with the Anti-CD40 Monoclonal Antibody KPL-404: Safety, Tolerability, Receptor Occupancy, and Suppression of T-Cell-Dependent Antibody Response,” J Pharmacol Exp T… [cited by applicant]